Skip to main content
. Author manuscript; available in PMC: 2015 Jan 4.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Aug 14;74(4):831–838. doi: 10.1007/s00280-014-2535-4

Fig. 2.

Fig. 2

a Boxplot of FMO3 genotype versus daunorubicin clearance. Individuals with FMO3-H1/H3 (n = 7) have significantly lower daunorubicin clearance than individuals with FMO3-H1/H1 (n = 8), p = 0.00829. b Boxplot of GSTP1 genotype versus daunorubicin clearance. Individuals with GSTP1*B/*B (n = 7) have significantly lower daunorubicin clearance than individuals with GSTP1*A/*A (n = 19), p = 0.0347